.png){kind=icon}
返回
NAMs: Beta testing needed
.png){kind=icon}
OA
AI
DOI：10.1016/j.cotox.2024.100490.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
A variety of new approach methodologies (NAMs) have already been developed for acute systemic and short-term toxicity, including in vitro, , in silico, , and omics methods. To advance their regulatory implementation, we suggest that beta testing of these methods in regulatory settings is urgently needed. There are several limitations to the use of NAMs for acute systemic and short-term toxicity, such as the lack of definitions for applicability domains, skewed reference data for validation, and the absence of representation of kinetic processes and multi-organ complexity. These limitations may lead to risks associated with the ordinary regulatory implementation, such as the application of methods to substances outside of their intended applicability domain or reduced predictivity due to a lack of mechanistic information or consideration of kinetics. We argue that this could be avoided by beta testing. Further benefits of beta testing would be the filling of in vivo data gaps and potentially improved validation with regard to human relevance of methods. In order to enhance the improvement, familiarisation, and acceptance of NAMs in the near future, it is essential for such concept of beta testing to rely on feedback loops between method testers and developers.
Keyword:
New approach methodologies
Acute toxicity
Short-term toxicity
Safe
harbour approach
Regulatory implementation of alternatives to animal
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
3.6
论文数:
237
被引数:
1.9K
机构
引用论文
Iron storage in macrophages and endothelial cells. histochemistry, ultrastructure, and clinical significance.png)
Blut
BlutIF0
PREAI
分享收藏Digital detection of dementia (D3): a study protocol for a pragmatic cluster-randomized trial examining the application of patient-reported outcomes and passive clinical decision support systems痴呆症的数字检测 (D3): 一项实用集群随机试验的研究方案，研究患者报告的结果和被动临床决策支持系统的应用Trials
OAAI
TrialsIF0
OAAI分享收藏分享收藏
查看更多内容